Evidence map›Paper›PMID 38422469›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Toward Application of Polygenic Risk Scores to Both Enhance and Deintensify Breast Cancer Screening.

Kara N Maxwell, Susan M Domchek

Abstract readEditorial
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Polygenic risk scores in the clinic: Health-system leaders and primary care providers weigh in.Genetics in medicine : official journal of the American College of Medical Genetics · 2025
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kara N MaxwellDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-8192-4202
Susan M DomchekDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-5914-7272

Funding

A genotype-phenotype study of tumors from patients with inherited mutations in DNA repair genesK08CA215312 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MAXWELL, KARA N · 2018 to 2022
$924k
Predicting Metastatic Progression of High Risk Localized Prostate CancerI01CX002622 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI Isla Pearl Garraway, BEATRICE S KNUDSEN · 2023 to 2026
–
Mutational processes underlying tumor development in United States VeteransI01CX002709 · VA · PHILADELPHIA VA MEDICAL CENTER · PI MICHAEL J KELLEY, KARA N MAXWELL · 2024 to 2026
–
CSRD VA I01 CX002622CSRD VA I01 CX002709NCI NIH HHS K08 CA215312
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsEarly Detection of CancerMultifactorial InheritanceFemaleGenetic Predisposition to DiseaseGenetic Risk ScoreHumansRisk AssessmentRisk Factors

Identifiers

PMID38422469
PMCPMC11095852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.